Novel Drug Sparks Hope for Targeting HER3 in NSCLC and Beyond
OncLive,
Patritumab deruxtecan, a novel antibody-drug conjugate, is emerging as a promising HER3-directed therapy in patients with non–sma…
Targeted Therapies Continue to Shape Future Breast Cancer Paradigm
OncLive,
With the identification of numerous molecular abnormalities that can affect treatment and the course of disease in patients…
NRG1 Fusions Hold Promise as Pan-tumor Target
OncLive,
The identification of chromosomal rearrangements that result in oncogenic gene fusions ushered in the era of molecularly…
Patritumab Deruxtecan Poised for Phase 2 Exploration in HER3+ Advanced CRC
OncLive,
The novel HER3-targeted antibody-drug conjugate (ADC) patritumab deruxtecan (U3-1402) is currently being investigated in a…